Australian Govt Needs To Tackle Low Biosimilar Awareness And Switching Concerns
This article was originally published in SRA
Executive Summary
The Australian government is facing something of an uphill struggle in convincing patients and healthcare professionals of the benefits of biosimilars, at least judging by a survey that has just been presented to the stakeholder reference group set up to advise on the government's biosimilar awareness strategy1.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.